SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease

Parkinson Disease Clinical Trial

— EMO-SPEECH-PD  

Official title:

SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05765110
• Other study ID #: 2022-01304
• Status: Recruiting
• Phase: N/A
• Start date: January 3, 2023
• Est. completion date: July 31, 2024

Study information

• Verified date: February 2023
• Source: University Hospital Inselspital, Berne
• Contact: Paul Krack, Prof.
• Phone: 31 66 4 03 71
• Email: paul.krack[@]insel.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

With this study, the investigators want to investigate whether computerized speech analysis can be used to reliably and objectively detect motor, emotional, and cognitive fluctuations in Parkinson's disease patients.

Description:

Parkinson's disease (PD) affects mobility (motor function), thought processes (cognition) and mood (emotion). The language is one of the most complex programs in humans. It contains information about mobility, thinking and mood at the same time. These three levels of agility, thinking and mood are subject to spontaneous fluctuations and can be influenced by external stimuli such as pictures that induce emotions. In addition, these three levels are influenced on the one hand by Parkinson's disease itself, and on the other hand by its treatment with medication or with deep brain stimulation (DBS). For this reason, the investigators would like to investigate language in Parkinson's disease patients in a very detailed computerized way for motor, cognitive and emotional elements for better management of therapies.

With this study, the investigators want to investigate whether computerized speech analysis can be used to reliably and objectively detect fluctuations in motor, mood, and thinking in Parkinson's disease patients.

Even in healthy subjects, speech changes in a situational manner, due to which the investigators will also include healthy subjects as a control group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: July 31, 2024
• Est. primary completion date: March 31, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 75 Years

Eligibility

Patients with Parkinson's Disease

Inclusion Criteria:

• Written informed consent

• Idiopathic PD according to the Movement Disorders Society Criteria;

• Age of participants > 30 and = 75 years;

• Treatment with or without bilateral deep brain stimulation in the subthalamic nucleus;

• Fluent in German or French

Exclusion Criteria:

• Dysarthria caused in addition by a condition other than PD (e.g. stroke, myasthenia);

• Clinical diagnosis of aphasia;

• Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.).

• Cognitive impairment (Montreal Cognitive Assessment (MoCa) < 24/30 points);

• Depression with acute suicidal ideation

Healthy Controls

Inclusion Criteria:

• Written informed consent

• Adults from 50-70 years old;

• Fluent in German or French

Exclusion Criteria:

• Diagnosis of Parkinson's disease;

• Cognitive impairment (Montreal Cognitive Assessment (MoCa) < 24/30 points);

• Suffering from brain disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.);

• Clinical diagnosis of aphasia, dysarthria, and stuttering;

• Suffering from or diagnosed with psychiatric illnesses according to DSM-V criteria

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Other:
• Dopaminergic OFF drug state
Experiment will be performed without dopaminergic medication
• DBS OFF state
Turning off the stimulation during experiment
• Dopaminergic ON drug state
Experiment will be performed with dopaminergic medication
• DBS ON state
Experiment will be performed with stimulation (ON condition)

Locations

Country	Name	City	State
Czechia	Czech Technical University Prague	Prague
Switzerland	University Hospital Inselspital, Berne	Bern

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Inselspital, Berne	Czech Technical University in Prague

Countries where clinical trial is conducted

Czechia,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Severity of non-motor aspects of experiences of Daily Living	Score on MDS-UPDRS parts I [0-52 pts.]. Higher scores in MDS-UPDRS-part I scale means more severe non-motor symptoms on experiences of Daily Living	< 2 weeks from the baseline visit
Other	Severity of motor aspects of experiences of Daily Living	Score on MDS-UPDRS parts II [0-52 pts.].Higher scores in MDS-UPDRS-part II scale means more severe motor symptoms on experiences of Daily Living	< 2 weeks from the baseline visit
Other	Severity of motor fluctuations	Score on MDS-UPDRS parts IV [0-24 pts.]. Higher scores in MDS-UPDRS-part IV scale means more severe motor fluctuations	< 2 weeks from the baseline visit
Other	Quality of life assessment	Score on Parkinson's Disease Questionnaire, 8 items (PDQ-8) [0-32 pts.]. Higher scores in PDQ-8 scale means worse quality of life	< 2 weeks from the baseline visit
Other	Dysarthria severity assessment	Score on Voice Handicap Index (VHI) [0-120 pts.]. Higher scores in VHI scale means more severe dysarthria (speech impairment)	< 2 weeks from the baseline visit
Other	Anxiety and depressive symptomatology	Score on Hospital Anxiety and Depression Scale (HADS) [0-60 pts.]. Higher scores in HADS scale means more severe anxiety and depressive symptoms	< 2 weeks from the baseline visit
Other	Apathetic symptomatology	Score on Starkstein Apathy Scale (SAS) [0-42 pts.]. Higher scores in SAS scale means more severe apathetic symptoms	< 2 weeks from the baseline visit
Other	Impulse-control disorders assessment	Score on Questionnaire for impulsive-compulsive disorders in Parkinson's Disease-Rating Scale (QUIP-RS) [0-112 pts.]. Higher scores in QUIP-RS scale means more severe impulsive-compulsive disorders	< 2 weeks from the baseline visit
Primary	Part I: Changes from baseline in best acoustic speech variables to detect changes of dopaminergic and stimulation motor effect in Parkinson's disease patients	A speech analyser software will allow extraction of basic motor acoustic speech features. The extracted variables that better index the dopaminergic medication or stimulation motor effect assessed with Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III - motor score [0-132 pts.] will be used as primary outcomes in this part. Higher scores in MDS-UPDRS part III means more severe motor symptoms.	Visit 2 (< 3 months)
Primary	Part II: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation neuropsychological effect in Parkinson's disease patients	A speech analyser software will allow extraction of basic acoustic speech features. For the linguistic domain several natural language variables will be extracted covering domains such as linguistic sense, coherence, and emotionality. The extracted variables that better index the dopaminergic medication or stimulation emotional effect assessed with Neuropsychiatric fluctuations scale (NFS) [0-60 pts.] will be used as primary outcomes in this part. Higher scores in NFS means more severe neuropsychiatric fluctuations.	Visit 2 (< 3 months)
Primary	Part III: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation cognitive effect in Parkinson's disease patients	A speech analyser software will allow extraction of basic acoustic speech features. For the linguistic domain several natural language variables will be extracted covering domains such as linguistic sense, coherence, and emotionality. The extracted variables that better index the dopaminergic medication or stimulation cognitive effect assessed with verbal fluency task will be used as primary outcomes in this part. Higher scores in Fluency task means better outcome.	Visit 2 (< 3 months)
Primary	Part III: Changes from baseline in best acoustic and linguistic speech variables to detect changes of dopaminergic and stimulation cognitive effect in Parkinson's disease patients	A speech analyser software will allow extraction of basic acoustic speech features. For the linguistic domain several natural language variables will be extracted covering domains such as linguistic sense, coherence, and emotionality. The extracted variables that better index the dopaminergic medication or stimulation cognitive effect assessed with Stroop test will be used as primary outcomes in this part. Higher scores in Stroop test means worse outcome.	Visit 2 (< 3 months)
Secondary	Dyskinesia severity	Score on Marconi dyskinesia rating scale [0-28 pts.]. Higher scores in Marconi dyskinesia rating scale means more severe dyskinesia.	At visit 1 (baseline) and visit 2 (< 3 months)
Secondary	Momentary mood state	Score on Visual Analogue Mood Scale (VAMS) [0-100 pts.]. Higher scores in VAMS means better mood.	At visit 1 (baseline) and visit 2 (< 3 months)
Secondary	Momentary anxiety state	Score on Visual Analogue Anxiety Scale (VAAS) [0-100 pts.]. Higher scores in VAAS means more anxiety.	At visit 1 (baseline) and visit 2 (< 3 months)
Secondary	Bradyphrenia assessment	Score on Bradyphrenia scale [0-72 pts.]. Higher scores in Bradyphrenia scale means more severe bradyphrenia.	At visit 1 (baseline) and visit 2 (< 3 months)